Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Nicolas M Van MieghemMartin UnverdorbenChristian HengstenbergHelge MöllmannRoxana MehranDiego López-OteroLuis Nombela-FrancoRaul MorenoPeter NordbeckHolger ThieleIrene LangJosé L ZamoranoFayaz ShawlMasanori YamamotoYusuke WatanabeKentaro HayashidaRainer HambrechtFelix MeinckePascal VranckxJames JinEric BoersmaJosep Rodés-CabauPatrick OhlmannPiera CapranzanoHyo-Soo KimThomas PilgrimRichard AndersonUsman BaberAnil DuggalPetra LaeisHans LanzCathy ChenMarco ValgimigliRoland VeltkampShigeru SaitoGeorge D Dangasnull nullPublished in: The New England journal of medicine (2021)
In patients with mainly prevalent atrial fibrillation who underwent successful TAVR, edoxaban was noninferior to vitamin K antagonists as determined by a hazard ratio margin of 38% for a composite primary outcome of adverse clinical events. The incidence of major bleeding was higher with edoxaban than with vitamin K antagonists. (Funded by Daiichi Sankyo; ENVISAGE-TAVI AF ClinicalTrials.gov number, NCT02943785.).
Keyphrases
- atrial fibrillation
- transcatheter aortic valve replacement
- aortic valve
- venous thromboembolism
- aortic stenosis
- direct oral anticoagulants
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- transcatheter aortic valve implantation
- heart failure
- ejection fraction
- percutaneous coronary intervention
- risk factors
- left ventricular
- coronary artery disease
- emergency department
- acute coronary syndrome
- electronic health record